157,995 Shares in Omnicell, Inc. $OMCL Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 157,995 shares of the company’s stock, valued at approximately $6,560,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Omnicell during the second quarter worth $313,044,000. Wellington Management Group LLP increased its stake in shares of Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares in the last quarter. Millennium Management LLC bought a new position in shares of Omnicell in the third quarter valued at about $25,625,000. First Light Asset Management LLC bought a new position in shares of Omnicell in the first quarter valued at about $16,351,000. Finally, Boston Partners acquired a new position in Omnicell during the 4th quarter worth about $20,805,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Wells Fargo & Company decreased their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Piper Sandler reissued an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday. Finally, Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Price Performance

Omnicell stock opened at $33.45 on Thursday. The business’s 50-day simple moving average is $40.04 and its 200 day simple moving average is $39.40. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of 39.82, a P/E/G ratio of 0.83 and a beta of 0.98. Omnicell, Inc. has a 12-month low of $29.06 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same period in the previous year, the business posted $0.45 EPS. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, research analysts anticipate that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.